🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Lincoln Pharmaceuticals Limited LINCOLN NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.lincolnpharma.com
Company Profile ↓
₹609.40
+9.76% 1Y
Mkt Cap₹1,220.61 Cr
P/E13.89
P/B1.61
Div. Yield0.29%
52W High₹758.15
52W Low₹444.20
Book Value₹378.25
EPS (TTM)₹43.88

Company Overview

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia. Lincoln Pharmaceuticals Limited was incorporated in 1979 and is based in Ahmedabad, India.

Why Investors Should Care

Reasonable Valuation

Trades at a P/E of 13.9, below the sector median of 40.0.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹671.03 Cr (+7.7% YoY); net profit ₹87.89 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +7.7%, earnings +6.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 9.9%, profit CAGR 6.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:9.94%
1 Year:7.67%

Compounded Profit Growth

5 Years:6.43%
1 Year:6.74%

Stock Price Performance

1 Year:+9.76%
6 Months:+25.37%
3 Months:+2.63%
1 Month:-6.67%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 53% of range
₹444.20 ₹758.15
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)43.84 · Neutral
Price Performance
1M-6.67%
3M+2.63%
6M+25.37%
1Y+9.76%
Valuation vs Sector

P/E of 13.89 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
13.89
Industry PE
39.97
Forward P/E est.
13.01
PEG Ratio
-
Book Value
₹378.25
Price to Book
1.61
P/S
1.82
EV/EBITDA
10.09
Dividend Yield
0.29%

Growth (CAGR)

Revenue 5Y
9.94%
Profit 5Y
6.43%
Revenue (YoY)
7.67%
Earnings (YoY)
6.74%

Profitability & Returns

ROCE
14.97%
ROE
11.60%
ROA
9.87%
Profit Margin
13.10%
Op Margin
12.40%
Gross Margin
53.63%
EPS (Latest Qtr)
₹5.81
EPS (TTM)
₹43.88

Balance Sheet & Liquidity

Debt/Equity
0.58
Quick Ratio
4.53
Current Ratio
5.25
Debt
₹4.42 Cr
Total Assets
₹890.40 Cr
Current Assets
₹583.06 Cr
Working Capital
₹472.01 Cr

Ownership

Promoter Holding
56.11%
Chg in Prom Hold
6.33%
FII / Inst Holding
1.07%
Chg in FII Hold
0.02%

Financial Snapshot

Enterprise Value
₹1,220.61 Cr
Total Revenue (TTM)
₹671.03 Cr
EBITDA
₹131.14 Cr
Free Cash Flow
₹80.32 Cr
Operating Cash Flow
₹106.36 Cr
Shares Outstanding
₹2.00 Cr
Gross Margin
53.63%
Payout Ratio
4.10%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 LINCOLN Lincoln Pharmaceuticals Limited NSEPHARMA 609.40 13.89 ₹1,220.61 Cr 0.29% 14.97% 11.60% 9.94% 6.43%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 112.00 Cr136.00 Cr156.00 Cr146.00 Cr142.00 Cr147.00 Cr161.00 Cr147.00 Cr168.18 Cr154.07 Cr163.36 Cr166.32 Cr187.28 Cr
Cost of Revenue --------80.15 Cr69.38 Cr76.75 Cr75.96 Cr89.07 Cr
Gross Profit --------88.03 Cr84.68 Cr86.62 Cr90.36 Cr98.21 Cr
Operating Expenses 96.00 Cr115.00 Cr125.00 Cr117.00 Cr124.00 Cr125.00 Cr133.00 Cr123.00 Cr64.54 Cr64.36 Cr64.81 Cr70.49 Cr77.03 Cr
Operating Income 15.00 Cr18.00 Cr28.00 Cr27.00 Cr15.00 Cr20.00 Cr25.00 Cr21.00 Cr23.49 Cr20.33 Cr21.81 Cr19.88 Cr21.17 Cr
EBITDA 17.00 Cr21.00 Cr31.00 Cr30.00 Cr18.00 Cr23.00 Cr28.00 Cr24.00 Cr19.84 Cr39.08 Cr32.66 Cr38.74 Cr20.66 Cr
Interest Expense 1.00 Cr0000001.00 Cr36.68 L20.98 L23.07 L29.81 L27.44 L
Pretax Income 17.00 Cr25.00 Cr37.00 Cr38.00 Cr22.00 Cr29.00 Cr35.00 Cr29.00 Cr16.25 Cr35.39 Cr28.81 Cr34.72 Cr16.70 Cr
Tax Provision 4.42 Cr6.25 Cr9.25 Cr9.88 Cr3.52 Cr5.80 Cr8.40 Cr8.12 Cr4.67 Cr7.71 Cr8.83 Cr6.12 Cr5.07 Cr
Net Income 13.00 Cr19.00 Cr28.00 Cr28.00 Cr19.00 Cr24.00 Cr26.00 Cr21.00 Cr11.57 Cr27.68 Cr19.98 Cr28.60 Cr11.63 Cr
Diluted EPS 6.279.4913.8014.009.2911.8213.1510.375.7813.829.9814.285.81

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 266.00 Cr400.00 Cr360.00 Cr361.00 Cr366.00 Cr386.00 Cr424.00 Cr-504.95 Cr571.22 Cr623.23 Cr671.03 Cr
Cost of Revenue --------243.09 Cr280.02 Cr291.32 Cr311.16 Cr
Gross Profit --------261.87 Cr291.20 Cr331.91 Cr359.87 Cr
Operating Expenses 240.00 Cr359.00 Cr313.00 Cr308.00 Cr299.00 Cr321.00 Cr337.00 Cr-181.19 Cr201.58 Cr243.32 Cr276.69 Cr
Operating Income 21.00 Cr36.00 Cr41.00 Cr47.00 Cr61.00 Cr59.00 Cr79.00 Cr-80.68 Cr89.62 Cr88.59 Cr83.18 Cr
EBITDA 26.00 Cr41.00 Cr47.00 Cr53.00 Cr68.00 Cr66.00 Cr87.00 Cr-111.28 Cr133.81 Cr123.97 Cr131.14 Cr
Interest Expense 8.00 Cr10.00 Cr7.00 Cr5.00 Cr4.00 Cr2.00 Cr2.00 Cr-1.64 Cr94.63 L1.88 Cr1.01 Cr
Pretax Income 20.00 Cr33.00 Cr37.00 Cr46.00 Cr62.00 Cr67.00 Cr84.00 Cr-100.48 Cr122.24 Cr109.19 Cr115.62 Cr
Tax Provision 4.80 Cr9.24 Cr9.25 Cr11.50 Cr13.64 Cr15.41 Cr21.84 Cr-27.58 Cr28.94 Cr26.84 Cr27.73 Cr
Net Income 15.00 Cr24.00 Cr28.00 Cr35.00 Cr49.00 Cr51.00 Cr62.00 Cr-72.90 Cr93.30 Cr82.35 Cr87.89 Cr
Diluted EPS 9.2014.5214.0617.3124.3625.7231.12-36.4046.5841.1143.88

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 258.00 Cr275.00 Cr305.00 Cr347.00 Cr366.00 Cr389.00 Cr452.00 Cr-587.42 Cr700.29 Cr797.01 Cr890.40 Cr
Current Assets --------367.21 Cr437.78 Cr499.94 Cr583.06 Cr
Cash & Equivalents --------5.05 Cr5.75 Cr13.41 Cr21.53 Cr
Inventory --------70.03 Cr77.17 Cr78.68 Cr80.11 Cr
Receivables --------136.33 Cr161.77 Cr166.40 Cr161.45 Cr
Total Liabilities --------84.95 Cr107.45 Cr125.34 Cr132.77 Cr
Current Liabilities --------72.15 Cr92.28 Cr106.22 Cr111.04 Cr
Long Term Debt -------0----
Total Debt 76.00 Cr78.00 Cr64.00 Cr61.00 Cr34.00 Cr5.00 Cr1.00 Cr2.04 Cr2.00 Cr1.07 Cr-4.42 Cr
Total Equity 111.00 Cr140.00 Cr192.00 Cr224.00 Cr269.00 Cr313.00 Cr366.00 Cr-502.47 Cr592.84 Cr671.67 Cr757.63 Cr
Shares Outstanding --------2.00 Cr2.00 Cr2.00 Cr2.00 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 25.00 Cr45.00 Cr25.00 Cr27.00 Cr53.00 Cr75.00 Cr69.00 Cr-39.26 Cr63.22 Cr93.02 Cr106.36 Cr
Investing Cash Flow 7.00 Cr-42.00 Cr-25.00 Cr-12.00 Cr-18.00 Cr-31.00 Cr-64.00 Cr--36.64 Cr-57.34 Cr-78.95 Cr-98.40 Cr
Financing Cash Flow -32.00 Cr-3.00 Cr0-11.00 Cr-36.00 Cr-38.00 Cr-6.00 Cr--4.50 Cr-5.18 Cr-6.40 Cr15.89 L
Capital Expenditure -4.00 Cr-34.00 Cr-18.00 Cr-10.00 Cr-15.00 Cr-7.00 Cr-8.00 Cr--14.28 Cr-39.61 Cr-19.24 Cr-26.04 Cr
Free Cash Flow 21.00 Cr11.00 Cr7.00 Cr17.00 Cr38.00 Cr68.00 Cr61.00 Cr-24.98 Cr23.60 Cr73.77 Cr80.32 Cr
Net Change in Cash -1.00 Cr-0-03.00 Cr-1.00 Cr7.00 Cr-1.00 Cr--1.88 Cr69.52 L7.67 Cr8.11 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------51.9%51.0%53.3%53.6%
Operating Margin % 7.9%9.0%11.4%13.0%16.7%15.3%18.6%-16.0%15.7%14.2%12.4%
Net Margin % 5.6%6.0%7.8%9.7%13.4%13.2%14.6%-14.4%16.3%13.2%13.1%
ROE % 13.5%17.1%14.6%15.6%18.2%16.3%16.9%-14.5%15.7%12.3%11.6%
ROCE % --------15.7%14.7%12.8%10.7%

Shareholding Pattern

Insiders
56.11%
Institutions
1.07%
Public Float
2.43%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LINCOLN

Google News ue, 14 Jul 2026

Dow Jones Leader Apple Hits Latest Buy Point; Datadog, Lincoln, Match In Or Near Buy Zones - Investor's Business Daily

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNaFg1V3dtMmE2a3FZeTBmeUpmdk1RdzVfcVMwZHRwR3M2aEhNV0VXVFlERThnMzR0dVVpN1VwbGFtUmNPOEViWVI5SEVMT2psRmhkbnVLNmxTN1JYMnZqT1d6a0ZxeXowVTRnd2dxY1EtZmc3UzUzOEFaSUN4Q3Z0cHlmVG1NVTltMlpFVm…

Google News Mon, 13 Jul 2026

LNC Stock Pops On Report Of Lincoln National’s Potential $5B Reinsurance Deal With Talcott - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPVjhicWpvZVNNbEh6b3VHekk0Wl95a01MQjRtZ3QyWWl5eElHcGZUMi02dXpXWngwMEg2VF9LYmkzcWZFb2ZSaWFFZnhTSFJSckY4WVhOLWs1azFTS0VWd2hjVG9JZWxOOEFOV05VSC1ndG16ZE1uS2Vic2tNNHBSOUFUWmllWUlvOXVlMn…

Google News ue, 14 Jul 2026

Is Lincoln National (LNC) Using Reinsurance to Quietly Redefine Its Risk and Capital Profile? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOYkZ1OHhTNWtIa0k0ZThnWmNvcWdTS2Y3THp5TmY3cmlsQTlkcVBNa0J4MXVRSTF3TmdUWDZVcVd6UFpGMTFUdHpCX1JvMTRZWkp6SlBtN3k2SmZGVnVXTXQ3bFJkTzFIQnpPdFdlZkhjWDRxTERuYm80UnJKR2RLRGFDaVVEMDBjV2lvZn…

Google News Mon, 13 Jul 2026

Lincoln National Corp. stock outperforms competitors on strong trading day - MarketWatch

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxNQ3R6ZGNkbmlqRmdTYi1OZnlYb1l5QzZLT3JmbjQyNm43NTF4VzZuZ21FMWVfMEpSaVgzODU0RVhfQjd1ZXdiSHBIeTk2NlRDalVUc1FzeW13ZU5rSS12NmhYdkVKaC0zVTM1a0o4RzUxUC1jMlEzdXdUcnl5Z1h2SW83bi1hbXBGcmtpLU…

Google News Mon, 06 Jul 2026

Lincoln Financial Group (LNC) Stock Trades Up, Here Is Why - StockStory

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQNGk0T0w4RmlIa0hXSHQyd2E4VVo4aXlaZUxkQXVNUUphSThFZERianJDSGUxQ05BRFRvdHZ6V1dsRWRDRFd2VW54dDRJUXlUZzdZcEtPYXM1c1NrNHpNMG1DNXVCU2VRdFdxSWF3ZFNDbnllN3ZacnZISUx6QUhCMjluQ3JIX24ybUFpZV…

Google News Mon, 13 Jul 2026

Lincoln National in talks for multibillion risk deal - report (LNC:NYSE) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPcG5UdGIxVFQ1am9TczFxZ2hONmRLcm5Bc1RHTnFVdjJIMkQ2M2M1VnRoQlk5N25GWmd6Z3c1QzBzVkVJdVEwZUNIVW9ka0MxZERmM09NaWJpY1F5ZVh4RWItRVZuaE5renNMRDNQNzhuZ0FEZTRoNENyYVRPY0NXQ2s3SVl5dW8zaGVxam…

LINCOLN — Frequently Asked Questions

What is the current share price of Lincoln Pharmaceuticals Limited (LINCOLN)?

As of 2026-07-15 09:52 IST, Lincoln Pharmaceuticals Limited (LINCOLN) trades at ₹609.40 on NSE. Its 52-week range is ₹444.20 to ₹758.15.

What is the market capitalisation of LINCOLN?

Lincoln Pharmaceuticals Limited (LINCOLN) has a market capitalisation of ₹1,220.61 Cr on NSE.

What is the P/E ratio of LINCOLN?

LINCOLN trades at a trailing price-to-earnings (P/E) ratio of 13.89. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 1.61.

Does LINCOLN pay a dividend?

Lincoln Pharmaceuticals Limited (LINCOLN) currently offers a dividend yield of 0.29%.

What is the return on equity (ROE) of LINCOLN?

LINCOLN has a return on equity (ROE) of 11.60%. Its return on capital employed (ROCE) is 14.97%.

Is LINCOLN a good stock to buy?

This page provides a data-driven analysis of Lincoln Pharmaceuticals Limited (LINCOLN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space